Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

Lucy S Witt; Danielle Barrios Steed; Eileen M Burd; Tugba Ozturk; Michelle H Davis; Sarah W Satola; David S Weiss; Jesse T Jacob

doi:10.1093/jac/dkac197

Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

J Antimicrob Chemother. 2022 Aug 25;77(9):2569-2571. doi: 10.1093/jac/dkac197.

Authors

Lucy S Witt^{1

2}, Danielle Barrios Steed¹, Eileen M Burd^{1

3

4}, Tugba Ozturk⁴, Michelle H Davis⁴, Sarah W Satola^{1

2

3

4}, David S Weiss^{1

2

4}, Jesse T Jacob^{1

2

4}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
² Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA, USA.
³ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
⁴ Emory Antibiotic Resistance Center, Atlanta, GA, USA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Bacteremia* / drug therapy
Cefiderocol
Cephalosporins / pharmacology
Cephalosporins / therapeutic use
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae
Microbial Sensitivity Tests
beta-Lactamases / genetics

Substances

Anti-Bacterial Agents
Cephalosporins
beta-Lactamases

Publication types

MeSH terms

Substances

Grants and funding